SCHEDULE: Adage Capital Discloses 6.27% Stake in ProQR

Adage Capital Management, L.P. and its principals have disclosed a 6.27% beneficial ownership stake in ProQR Therapeutics N.V. as of June 30, 2025.

Summary

• Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 6,601,938 ordinary shares of ProQR Therapeutics N.V.
• This represents 6.27% of ProQR Therapeutics N.V.'s total outstanding ordinary shares.
• The ownership is primarily held through Adage Capital Partners, L.P., with shared voting and dispositive power over all 6,601,938 shares.
• The percentage of class is calculated based on 105,212,527 ordinary shares outstanding as of December 31, 2024, as reported in the company's Form 20-F.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, providing factual data without expressing positive or negative sentiment regarding the company's performance or outlook.

Positives

• A significant institutional investor, Adage Capital Management, L.P., maintains a substantial stake in ProQR Therapeutics N.V., indicating continued investment interest.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investment in a biotechnology company. It does not provide broader industry trends or specific competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

ProQR Therapeutics, Adage Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Investment Management, Biotechnology